Kucka, M, Tomić, M, Bjelobaba, I, Stojilkovic, SS, Budimirovic, DB. Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs. Sci Rep
2015; 5: 8902.
Melkersson, K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry
2005; 66: 761–7.
Melkersson, KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol
2006; 21: 529–32.
O'Keane, V, Meaney, AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?
J Clin Psychopharmacol
2005; 25: 26–31.
Volavka, J, Czobor, P, Cooper, TB, Sheitman, B, Lindenmayer, JP, Citrome, L, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry
2004; 65: 57–61.
Beumont, PJ, Corker, CS, Friesen, HG, Kolakowska, T, Mandelbrote, M, Marshall, J, et al. The effects of phenothiazines on endocrine function: II. Effects in men and post-menopausal women. Br J Psychiatry
1974; 124: 420–30.
Beumont, PJ, Gelder, MG, Friesen, GH, Harris, GW, MacKinnon, PC, Mandelbrote, BM, et al. The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea. Br J Psychiatry
1974; 124: 413–9.
Rosenberg, KP, Bleiberg, KL, Koscis, J, Gross, C. A survey of sexual side-effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther
2003; 29: 289–96.
Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Örey, D, Richter, F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet
2013; 382: 951–62.
Jauhar, S, Guloksuz, S, Andlauer, O, Lydall, G, Marques, JG, Mendonca, L, et al. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?
2012; 12: 27.
Peuskens, J, Pani, L, Detraux, J, De Hert, M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs
2014; 28: 421–53.
Cavallaro, R, Cocchi, F, Angelone, SM, Lattuada, E, Smeraldi, E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry
2004; 65: 187–90.
Stroup, TS, McEvoy, JP, Ring, KD, Hamer, RH, LaVange, LM, Swartz, MS, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry
2011; 168: 947–56.
Lee, MS, Song, HC, An, H, Yang, J, Ko, YH, Jung, IK, et al. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, singleblind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci
2010; 64: 19–27.
Urban, JD, Vargas, GA, von Zastrow, M, Mailman, RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology
2007; 32: 67–77.
Natesan, S, Reckless, GE, Nobrega, JN, Fletcher, PJ, Kapur, S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology
2006; 31: 1854–63.
Mailman, R, Murthy, V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
Curr Pharm Des
2010; 16: 488–501.
Shapiro, DA, Renock, S, Arrington, E, Chiodo, LA, Liu, L-X, Sibley, DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology
2003; 28: 1400–11.
Li, X, Tang, Y, Wang, C. Adjunctive aripiprazole versus placebo for antipsychoticinduced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One
2013; 8: e70179.
Chen, HZ, Niu, FR, Qian, MC, Yu, BR, Shen, XH, Yang, SG, et al. The effect of aripiprazole plus risperidone on the level of hyperprolactinemia of male patients with schizophrenia. Zhong Hua Jing Shen Ke Za Zhi
2009; 42: 224–7.
Kane, JM, Correll, CU, Goff, DC, Kirkpatrick, B, Marder, SR, Vester-Blokland, E, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry
2009; 70: 1348–57.
Shim, J-C, Shin, JG, Kelly, DL, Jung, D-U, Seo, Y-S, Liu, K-H, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry
2007; 164: 1404–10.
Moher, D, Hopewell, S, Schulz, KF, Montori, V, Gotzsche, PC, Devereaux, PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ
2010; 340: c869.
First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for Axis I DSM-IV Disorders.
Biometrics Research, 1994.
Overall, JE, Gorham, DR. The brief psychiatric rating scale. Psychol Rep
1962; 10: 799–812.
Simpson, GM, Angus, JW. A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand Suppl
1970; 212: 11–9.
Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry
1989; 154: 672–6.
McGahuey, CA, Gelenberg, AJ, Laukes, CA, Moreno, FA, Delgado, PL, McKnight, KM, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther
2000; 26: 25–40.
Kelly, DL, Conley, RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology
2006; 31: 340–6.
Schulster, D, Gaines Das, RE, Jeffcoate, SL. International Standards for human prolactin: calibration by international collaborative study. J Endocrinol
1989; 121: 157–66.
Cooper, HM, Hedges, LV, Valentine, JC. The Handbook of Research Synthesis and Meta-analysis.
Russell Sage Foundation, 2009.
Carboni, L, Negri, M, Michielin, F, Bertani, S, Fratte, SD, Oliosi, B, et al. Slow dissociation of partial agonists from the D2 receptor is linked to reduced prolactin release. Int J Neuropsychopharmacol
2012; 15: 645–56.
Davies, MA, Sheffler, DJ, Roth, BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev.
2004; 10: 317–36.
Yasui-Furukori, N, Furukori, H, Sugawara, N, Fujii, A, Kaneko, S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol
2010; 30: 596–9.
Schlechte, JA. Clinical practice. Prolactinoma. N Engl J Med
2003; 349: 2035–41.
Hanssens, L, L'Italien, G, Loze, J-Y, Marcus, RN, Pans, M, Kerselaers, W. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry
2008; 8: 95.
Takeuchi, H, Remington, G. A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology (Berl)
2013; 228: 175–85
Takeuchi, H, Uchida, H, Suzuki, T, Watanabe, K, Kashima, H. Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study. J Clin Psychopharmacol
2009; 29: 394–5.
Gugger, JJ, Tam, CL, Ashby, CR. Is there a link between aripiprazole and treatment-emergent psychosis?
2011; 10: 53–8.
Manschreck, TC, Boshes, RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry
2007; 15: 245–58.
Chen, CK, Huang, YS, Ree, SC, Hsiao, CC. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry
2010; 34: 1495–9.
Levy, A. Interpreting raised serum prolactin results. BMJ
2014; 348: g3207.